Global Artificial Intelligence In Precision Medicine Market Insights Forecasts to 2032
- The Artificial Intelligence In Precision Medicine Market Size was valued at USD 1.28 Billion in 2022.
- The Market Size is Growing at a CAGR of 16.3% from 2022 to 2032
- The Global Artificial Intelligence In Precision Medicine Market Size is expected to reach USD 5.79 Billion by 2032
- Europe is expected to grow significant during the forecast period
Get more details on this report -
The Global Artificial Intelligence In Precision Medicine Market Size is expected to reach USD 5.79 Billion by 2032, at a CAGR of 16.3% during the forecast period 2023 to 2032.
Artificial Intelligence (AI) has revolutionized the field of precision medicine by harnessing the power of data analytics and machine learning to personalize healthcare in unprecedented ways. By analyzing vast datasets of genomic, clinical, and patient information, AI algorithms can identify subtle patterns and correlations that human experts might overlook. This enables AI to assist in disease diagnosis, treatment selection, and prognosis prediction with remarkable accuracy. AI-driven tools like predictive modeling, natural language processing, and image recognition have transformed medical research and clinical practice. They empower clinicians to tailor treatments and interventions to individual patients, optimizing outcomes and minimizing adverse effects. Additionally, AI has accelerated drug discovery and development by efficiently screening compounds and identifying potential therapies. As AI continues to advance, it holds the promise of delivering more precise, efficient, and patient-centered healthcare in the realm of precision medicine.
This research report categorizes the market for artificial intelligence in precision medicine market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the artificial intelligence in precision medicine market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the artificial intelligence in precision medicine market.
Global Artificial Intelligence In Precision Medicine Market Report Coverage
|Market Size in 2022:||USD 1.28 Billion|
|Forecast Period 2022-2032 CAGR:||16.3%|
|2032 Value Projection:||USD 5.79 Billion|
|Historical Data for:||2018-2021|
|No. of Pages:||200|
|Tables, Charts & Figures:||110|
|Segments covered:||By Technology, By Component, By Therapeutic Application, By Region and COVID-19 Impact Analysis|
|Companies Covered:||BioXcel Therapeutics, Inc., Sanofi S.A., NVIDIA Corp., Google Inc., IBM, Microsoft, Intel Corp., AstraZeneca Plc, GE HealthCare, Enlitic, Inc., and other key vendors.|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
The growing adoption of artificial intelligence (AI) in precision medicine is driven by several key factors that collectively contribute to the expansion of this burgeoning market. The he increasing volume of healthcare data, including genomics, clinical records, and imaging data, is a significant driver. AI excels at processing and deriving insights from these data, enabling more accurate disease diagnosis, treatment selection, and patient stratification. Moreover, the rising prevalence of chronic diseases and the need for tailored therapies have fueled the demand for AI-driven solutions that can personalize healthcare interventions, optimize treatment regimens, and enhance patient outcomes. Another crucial driver is the continuous advancement of AI technology itself, particularly in machine learning and deep learning techniques. These innovations enable AI systems to learn from complex datasets and adapt their algorithms over time, improving their predictive and diagnostic capabilities. Furthermore, the increasing availability of computational resources, including cloud computing and high-performance GPUs, has made it more accessible for healthcare organizations to deploy AI solutions. Regulatory support and initiatives from governments and healthcare institutions worldwide play a pivotal role in propelling the AI in precision medicine market forward. These entities recognize the potential of AI to improve patient care, reduce healthcare costs, and drive medical research advancements. Consequently, they are incentivizing AI adoption through funding, policy reforms, and streamlined regulatory pathways, which encourages investment and innovation in the field. In addition, the pharmaceutical and biotechnology industries are embracing AI to expedite drug discovery and development processes. AI-driven drug discovery models can identify novel drug candidates, predict their efficacy, and optimize clinical trial designs, ultimately accelerating the time-to-market for new therapies. The increasing patient awareness and demand for personalized healthcare solutions are driving the adoption of AI in precision medicine. Patients are seeking more proactive and customized treatment options, and AI can deliver on these expectations by tailoring interventions to individual genetic and clinical profiles.
Despite its promising potential, the adoption of Artificial Intelligence (AI) in the precision medicine market faces several notable restraints. First, concerns related to data privacy and security are substantial, as the sensitive nature of medical data requires robust safeguards and compliance with stringent regulations. Additionally, the high cost of implementing AI technologies, including infrastructure and training, can be a significant barrier for healthcare institutions. Interpretability and transparency of AI algorithms are also challenges, as understanding the rationale behind AI-driven decisions is crucial for clinical acceptance. Furthermore, the need for extensive validation and regulatory approvals can slow down the integration of AI solutions into clinical practice, hindering their rapid deployment and adoption.
- In 2022, the deep learning segment accounted for around 32.7% market share
On the basis of the technology, the global artificial intelligence in precision medicine market is segmented into deep learning, querying method, natural language processing, and context-aware processing. The dominance of the deep learning segment in the AI market can be attributed to its exceptional ability to process and analyze vast and complex datasets, making it especially well-suited for applications in healthcare, including precision medicine. Deep learning algorithms, such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs), excel in image analysis, natural language processing, and pattern recognition tasks. In precision medicine, these capabilities enable accurate disease diagnosis, treatment recommendations, and patient stratification.
- The software segment held the largest market with more than 41.3% revenue share in 2022
Based on the component, the global artificial intelligence in precision medicine market is segmented into hardware, software, and service. The dominance of the software segment in the market can be attributed to several factors. Software solutions play a pivotal role in harnessing the power of artificial intelligence and machine learning for precision medicine. They enable the development and deployment of sophisticated algorithms and models that analyze vast healthcare datasets, including genomic and clinical data. These software tools provide healthcare professionals with actionable insights, aiding in disease diagnosis, treatment selection, and patient care optimization. Additionally, software solutions often offer scalability and adaptability, making them integral to the widespread adoption of AI in precision medicine, ultimately securing the largest market share.
- The oncology segment is expected to grow at a CAGR of around 17.3% during the forecast period
Based on the therapeutic application, the global artificial intelligence in precision medicine market is segmented into oncology, cardiology, neurology, respiratory, and others. The rapid growth expected in the oncology segment can be attributed to cancer being a major global health concern, and precision medicine holds great promise in improving cancer diagnosis and treatment. AI technologies can analyze diverse data sources, such as genomics and imaging, to identify personalized treatment options and predict treatment responses. Additionally, the increasing incidence of cancer cases, coupled with a growing understanding of the molecular basis of cancer, creates a fertile ground for AI-driven innovations. Consequently, the oncology sector is poised to witness accelerated adoption and substantial growth in the coming years.
Regional Segment Analysis of the Artificial Intelligence In Precision Medicine Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America dominated the market with more than 28.2% revenue share in 2022.
Get more details on this report -
Based on region, North America has consistently dominated the AI in precision medicine market, primarily owing to its well-established healthcare infrastructure, substantial investments in research and development, and a large pool of healthcare data. The region boasts a robust ecosystem of pharmaceutical and biotech companies, academic institutions, and technology firms, all actively driving AI innovation in precision medicine. Moreover, favorable regulatory frameworks and government support for healthcare innovation have further propelled North America's leadership in this market. The availability of skilled professionals and a high level of awareness about the benefits of AI in healthcare contribute to its significant revenue share in the sector.
Europe is projected to experience substantial growth in the AI in precision medicine market during the forecast period. This growth is attributed to increasing investments in healthcare technology, supportive government policies, and a growing emphasis on personalized medicine. European countries have been actively collaborating on large-scale genomics initiatives and data sharing, fostering an environment conducive to AI-driven advancements in healthcare. Additionally, a rising prevalence of chronic diseases and a commitment to improving patient outcomes are driving the adoption of AI solutions, positioning Europe as a key growth region in the field of precision medicine.
- In July 2022, Certara, Inc., a biostimulation pioneer, has announced a two-year cooperation with Memorial Sloan Kettering Cancer Centre to develop new biosimulation software. This partnership will assist firms in developing a biosimulation platform for CAR T-cell therapy.
- In September 2022, Google collaborated with iCAD, Inc. to enhance breast cancer diagnosis and risk assessment in the near term. Furthermore, the collaboration would focus on improving access to mammography technology through cloud-based solutions.
The report offers the appropriate analysis of the key organizations/companies involved within the global artificial intelligence in precision medicine market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Companies:
- BioXcel Therapeutics, Inc.
- Sanofi S.A.
- NVIDIA Corp.
- Google Inc.
- Intel Corp.
- AstraZeneca Plc
- GE HealthCare
- Enlitic, Inc.
Key Target Audience
- Market Players
- Government Authorities
- Consulting and Research Firm
- Venture Capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at global, regional, and country levels from 2019 to 2032. Spherical Insights has segmented the global artificial intelligence in precision medicine market based on the below-mentioned segments:
Artificial Intelligence In Precision Medicine Market, By Technology
- Deep Learning
- Querying Method
- Natural Language Processing
- Context-Aware Processing
Artificial Intelligence In Precision Medicine Market, By Component
Artificial Intelligence In Precision Medicine Market, By Therapeutic Application
Artificial Intelligence In Precision Medicine Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?